Pooled efficacy favored ravulizumab, improving QMG (MD –2.91) and MG-ADL (MD –2.64) after ~25 weeks, despite substantial between-study heterogeneity. Clinically meaningful MG-ADL response (≥2-point ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results